initiative  OCTALFA’s mission is two fold : to facilitate innovation and provide support to vulnerable people.

Initiative  OCTALFA works to bring about innovation in healthcare by incubating innovative startups in France..

Initiative  OCTALFA also supports projects aimed at improving quality of life for cancer patients and disabled people in France and Madagascar.


OCTALFA creates, funds and manages young innovative companies
OTONNALE incubates innovative projects until they mature into fledgling companies
The corporate foundation Fondation Dominique & Tom Alberici – OCTALFA supports charity and non-profit projects addressing the challenges surrounding cancer and disabilities in France and Madagascar
The endowment fund Institut Dominique & Tom Alberici raises additional funds for projects supported by our corporate foundation


  • Gilles Alberici

    Gilles has 30 years of experience in the pharmaceutical and biotechnology sectors. He created and developedOPi, Pharmaceuticals for Rare Diseases and has taken more than ten products through clinical trials.

  • Julien Alberici
    Managing Director

    Julien is a graduate of EMLYON Business School and iaelyon management school. He has worked as a consultant in innovation management, business development andfinancial analysis,and is currently the Chief Executive Officer and co-founder ofMathym.

  • Jeremy Bastid
    Project Manager

    Jeremy is a pharmacist and oncologist, who specialises inimmuno-oncology. He joinedinitiative OCTALFA in 2010 and manages OREGABiotech asChief Operating Officer.

  • Annie Beucler
    Administrative Manager

    Annie Beucler joined initiative OCTALFA as Administrative Manager in 2013. Annie has worked for a number of SMEs specialised in renewable energy in France and Brazil.


Formed in 2006, OCTALFA is the fruit of previous work carried out by Gilles Alberici, in particular during his time at OPi, a company that develops drugs for orphan diseases.

OCTALFA began by helping established innovative companies with financing operations. It founded and/or invested in 14 companies in France.Since 2016, OCTALFAconcentrates its efforts to the development and management of its subsidiaries.

OTONNALEincubates innovative industrial or academic projects selected by initiative  OCTALFA until they reach maturity.

Spearheaded by Dominique Alberici, OCTALFA created the OCTALFA Corporate Foundation in 2008 to provide help for cancer patients and disabled people. The corporate foundation was named Fondation Dominique & Tom Alberici – OCTALFA in 2011, following the passing away of Tom, Dominique and Gilles’ son.

Founded in 2012, the endowment fund Institut Dominique & Tom Alberici complements the corporate foundation’s activities by supporting charity projects that require both a more hands-on approach and additional funding. This funding is provided by OCTALFA and our donors.


  • Antagene joints Cerba Healthcare

    ANTAGENE joins CERBA VET to form a European veterinary diagnostic leader

  • Alizé Pharma III presents preclinical results in osteoporosis

    The HBD1 peptide exhibited strong bone anabolic potency in a model of post-menopausal osteoporosis

  • OREGA Biotech strengthens its intellectual property

    Notices of allowance from EPO for two strategic patents.

  • Three projects supported by our Foundation

    On 7th of July 2016, the Board of Directors of the Foundation decided to support Handi Rhône Services (guide « Living well at home »), Audition Solidarité (hearing aids for the children of AKA MA school), Arche de Lyon (shared housing).

  • Graftys granted key U.S. patent

    This granted application covers GRFT-R02, an innovative osteogenic biomaterial for bone tissue regeneration.

  • JHAM : Jumelage Handicap Aide Madagascar

    Our project, JHAM, enters its second phase. Specific trainings will be offered to Malagasy centers in January 2017. They will be provided by young retirees of Lyon centers for disabled people. It is planned to send a second container with materials at fall 2016.

  • Alizé Pharma II acquired by Jazz Pharmaceuticals

    This all-cash transaction closed in March 2016 is valued at up to €18 million.

  • Graftys announces regulatory clearance in Australia and in Canada

    Graftys will market Graftys® Quickset in these countries.